Clinical trials: Hepatobiliary Disorders
HIV Infections, Fatty Liver Disease
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression…
- Trial name
- MAFALDA-R (NCT05898841)
- Testing
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion SEIMC-GESIDA
Hepatitis C, Chronic, Liver Diseases
The Patient-Reported Outcomes Project of HCV-TARGET
The PROP UP research study is funded by The Patient Centered Outcomes Research Institute (PCORI). PROP UP is a multi-centered prospective observational study that will evaluate all-oral treatment regimens for chronic hepatitis C…
- Trial name
- PROP-UP (NCT02601820)
- Where
- 11 sites in United States
- Volunteers
- 1,601 people
- Sponsor
- University of North Carolina, Chapel Hill
Enteral and Supplement Feeds Adverse Reaction, Nutrition Deficiency Due to Insufficient Food
How Well do we Feed the Critically Ill Patients
The present prospective observational multicentric study will assess the nutritional status of critically ill patients, cumulative calorie and protein balance and the effect of calorie and protein balance on clinical outcomes.
- Conditions
- Enteral and Supplement Feeds Adverse Reaction, Nutrition Deficiency Due to Insufficient Food, Critically Ill, Parenteral Nutrition Associated Liver Disease
- Trial name
- WE-FEED (NCT05347888)
- Testing
- Nutritional therapy
- Where
- United Arab Emirates
- Volunteers
- 1,000 people
- Sponsor
- NMC Specialty Hospital
Hepatitis B, Chronic
Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study
This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treated patients with chronic hepatitis B
- Trial name
- MAFLD-HBV 1 (NCT05708560)
- Where
- 3 sites in Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
NAFLD, Diet Habit
Exploring the Mechanism of Dietary Pattern Improving MAFLD
investigators plan to observe the changes of biochemical indicators, body composition, gut microbiota, metabolomics in patients at different periods through balanced diet and Low-carbohydrate diet, so as to determine the…
- Trial name
- NCT05960396
- Testing
- Diet intervention
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are…
- Trial name
- AGAINST-PLD (NCT05478083)
- Testing
- Leuprorelin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Hepatobiliary Diseases
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases.
- Trial name
- NCT01200082
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Genotype 1 Chronic Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects.
- Trial name
- NCT00606086
- Testing
- GI-5005, Pegylated Interferon and Ribavirin
- Where
- 25 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlobeImmune
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Clinical Pharmacology, Healthy Volunteer Study
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
This study is for research purposes only and will not treat any disease or condition you may have. The study is an open label and single dose study; open label means that you, the study doctor and study staff will know which…
- Trial name
- NCT01835561
- Testing
- Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Celgene
Non-Alcoholic Fatty Liver Disease
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty…
- Trial name
- AVAIL (NCT04807868)
- Testing
- Standard of care liver biopsy, Fibroscan, Biospecimen Collection
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Liver Diseases
A Research Study on Etavopivat in Participants With and Without Liver Disease
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls).
- Trial name
- NCT06336018
- Testing
- Etavopivat
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
NASH, NAFLD
Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one…
- Trial name
- MODELS (NCT06888310)
- Testing
- extra blood sampling
- Where
- Italy
- Volunteers
- 408 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
Healthy Liver - Healthy Brain
People with liver disease report difficulties with attention and problem-solving skills. Diet plays an important role in the development of liver disease and/or pre-diabetes.
- Conditions
- Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
- Trial name
- NCT05216796
- Testing
- Diet Intervention
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Metabolic Dysfunction-associated Fatty Liver Disease
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
- Trial name
- NCT06061640
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Non-Alcoholic Fatty Liver Disease
Efficacy of Phosphatidylcholine in NAFLD
This study evaluates efficacy of Phosphatidylcholine in addition to life style modification and patient health education by clinical Pharmacist in the Management of Non Alcoholic Fatty Liver NAFLD.
- Trial name
- NCT04411862
- Testing
- Phosphatidyl Choline, Lifestyle modification
- Volunteers
- 100 people
- Sponsor
- Nehal Abou Seada
Non Alcoholic Fatty Liver Disease
Genetics of Fatty Liver Disease in Children
This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents.
- Trial name
- NCT01966627
- Testing
- ogtt, genotyping, abdominal and liver magnetic resonance imaging
- Where
- United States
- Volunteers
- 381 people
- Sponsor
- Yale University
Infection
Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch
Observation of the use of intravenous antibiotics in medical clinic of Sorlandet Hospital, Norway. Suggestions of criteria for the switch from intravenous to oral administration of antibiotics.
- Trial name
- NCT00763373
- Testing
- Implementation of antibiotic switch guidelines
- Where
- 2 sites in Norway
- Volunteers
- 187 people
- Sponsor
- Sorlandet Hospital HF
Predictors of Response to HCV Tretment
Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment
assessment of very rapid virological response and rapid virological response as predictors of response to sofosbuvir and daclatasvir in treatment of cirrhotic and non-cirrhotic patients with HCV, eligible to treatment.
- Trial name
- NCT03480269
- Volunteers
- 100 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.